CAJ | 학술논문

曲贝替定（Yondelis R ，Trabectedin）是一种新的非铂类抗肿瘤药物，有独特的抗肿瘤机制，不良反应主要为可逆性肝脏损害。 Trabectedin的心脏毒性低，可以和蒽环类抗肿瘤药物联合应用，目前已应用于复发性卵巢癌的治疗。临床可选用的治疗方案有单药3周方案、单药周疗和联合蒽环类药物方案，其中联合方案疗效最好。Trabectedin对铂类敏感的复发性卵巢癌有较好的疗效，特别是对无铂间隔期（treatment-free interval，TFI）为6~12个月的复发性卵巢癌疗效显著，但对铂类耐药及难治性卵巢癌的疗效不明显。应用Trabectedin可延长TFI，为以后再次进行铂类药物治疗创造条件。
곡패체정（Yondelis R ，Trabectedin）시일충신적비박류항종류약물，유독특적항종류궤제，불량반응주요위가역성간장손해。 Trabectedin적심장독성저，가이화은배류항종류약물연합응용，목전이응용우복발성란소암적치료。림상가선용적치료방안유단약3주방안、단약주료화연합은배류약물방안，기중연합방안료효최호。Trabectedin대박류민감적복발성란소암유교호적료효，특별시대무박간격기（treatment-free interval，TFI）위6~12개월적복발성란소암료효현저，단대박류내약급난치성란소암적료효불명현。응용Trabectedin가연장TFI，위이후재차진행박류약물치료창조조건。
Trabectedin (Yondelis R ) is a new non-platinum antineoplastic drug with a unique antitumor mechanism. It′s main side effect is the reversible liver injury, and it′s cardiac toxicity is low. Trabectedin can be applied with anthracycline-based drugs in the treatment of recurrent ovarian cancer. The optional treatment clinically include:single drug 3 weeks plan, single drug weekly therapy,combined anthracycline-based drugs,the best effect is the in combinational scheme. Trabectedin make satisfied curative effect in platinum sensitive recurrent ovarian cancer ,especially treatment-free interval (TFI) 6-12 month. The platinum resistance and refractory ovarian cancer curative effect is not obvious. Application of Trabectedin can extend the TFI ,as to create conditions for using platinum drugs again.